98 related articles for article (PubMed ID: 16716801)
1. Unresolved issues in the chemotherapeutic management of gynecologic malignancies.
Markman M
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S33-8. PubMed ID: 16716801
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy in epithelial ovarian cancer.
Wang J; Li AJ; Karlan BY
Curr Womens Health Rep; 2002 Feb; 2(1):20-6. PubMed ID: 12112979
[TBL] [Abstract][Full Text] [Related]
3. Role of chemotherapy in the management of epithelial ovarian cancer.
Reed NS; Sadozye AH
Expert Rev Anticancer Ther; 2005 Feb; 5(1):139-47. PubMed ID: 15757446
[TBL] [Abstract][Full Text] [Related]
4. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.
Kyrgiou M; Salanti G; Pavlidis N; Paraskevaidis E; Ioannidis JP
J Natl Cancer Inst; 2006 Nov; 98(22):1655-63. PubMed ID: 17105988
[TBL] [Abstract][Full Text] [Related]
5. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
6. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
7. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
8. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
9. Role of chemotherapy in the management of ovarian cancer.
Markman M
Expert Rev Anticancer Ther; 2002 Feb; 2(1):90-6. PubMed ID: 12113074
[TBL] [Abstract][Full Text] [Related]
10. The role of maintenance therapy and novel taxanes in ovarian cancer.
Herzog TJ; Coleman RL; Markman M; Cella D; Thigpen JT
Gynecol Oncol; 2006 Aug; 102(2):218-25. PubMed ID: 16460787
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.
Bristow RE; Santillan A; Salani R; Diaz-Montes TP; Giuntoli RL; Meisner BC; Armstrong DK; Frick KD
Gynecol Oncol; 2007 Sep; 106(3):476-81. PubMed ID: 17688927
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of epithelial ovarian cancer].
Langmár Z; Csömör S
Orv Hetil; 2006 Aug; 147(34):1627-32. PubMed ID: 17017677
[TBL] [Abstract][Full Text] [Related]
13. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of epithelial ovarian cancer.
Bhoola S; Hoskins WJ
Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
[TBL] [Abstract][Full Text] [Related]
15. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
Pignata S; Scambia G; Pisano C; Breda E; Di Maio M; Greggi S; Ferrandina G; Lorusso D; Zagonel V; Febbraro A; Riva N; De Rosa V; Gallo C; Perrone F;
Br J Cancer; 2007 Jun; 96(11):1639-43. PubMed ID: 17486128
[TBL] [Abstract][Full Text] [Related]
16. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
[TBL] [Abstract][Full Text] [Related]
17. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
Gao KF; Liu FY; Chen FJ; Feng YL
Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
20. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist].
Sugiyama T; Yoshizaki A; Hatayama S
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]